Cell Reports: Medicine 2023 February 21 [Link]
Nishanth Ulhas Nair, Qun Jiang, Jun Stephen Wei, Vikram Alexander Misra, Betsy Morrow, Chimene Kesserwan, Leandro C Hermida, Joo Sang Lee, Idrees Mian, Jingli Zhang, Alexandra Lebensohn, Markku Miettinen, Manjistha Sengupta, Javed Khan, Eytan Ruppin, Raffit Hassan
Malignant mesothelioma is an aggressive cancer with limited treatment options and poor prognosis. A better understanding of mesothelioma genomics and transcriptomics could advance therapies. Here, we present a mesothelioma cohort of 122 patients along with their germline and tumor whole-exome and tumor RNA sequencing data as well as phenotypic and drug response information. We identify a 48-gene prognostic signature that is highly predictive of mesothelioma patient survival, including CCNB1, the expression of which is highly predictive of patient survival on its own. In addition, we analyze the transcriptomics data to study the tumor immune microenvironment and identify synthetic-lethality-based signatures predictive of response to therapy. This germline and somatic whole-exome sequencing as well as transcriptomics data from the same patient are a valuable resource to address important biological questions, including prognostic biomarkers and determinants of treatment response in mesothelioma.